- Home
- AZN vs MRK Comparison
AZN vs MRK Comparison
Compare AZN & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZN | MRK |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9B | 260.2B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | AZN | MRK |
|---|---|---|
| Price | $95.61 | $110.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 15 |
| Target Price | N/A | ★ $115.27 |
| AVG Volume (30 Days) | 4.8M | ★ 14.3M |
| Earning Date | 02-05-2026 | 02-03-2026 |
| Dividend Yield | 1.63% | ★ 3.06% |
| EPS Growth | 45.02 | ★ 58.08 |
| EPS | 6.02 | ★ 7.56 |
| Revenue | $58,127,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $11.40 | $1.98 |
| Revenue Next Year | $6.06 | $4.94 |
| P/E Ratio | $15.62 | ★ $14.69 |
| Revenue Growth | ★ 13.52 | 1.68 |
| 52 Week Low | $61.24 | $73.31 |
| 52 Week High | $96.51 | $112.90 |
Technical Indicators
Market Signals| Indicator | AZN | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 73.16 |
| Support Level | $93.22 | $104.43 |
| Resistance Level | $96.51 | $112.90 |
| Average True Range (ATR) | 1.40 | 2.19 |
| MACD | 0.20 | 0.30 |
| Stochastic Oscillator | 87.54 | 82.10 |
Price Performance
Historical ComparisonAbout AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).